The need for biosimilars in the USA: Obstacles and solutions

Biologics are of major importance to the US medical system. However the increasing cost of these medications has become a major issue. The economic impact of these products and their cost is reviewed, and how this is affecting their availability. Also, the economic impact on patients and their families is significant. The development of biosimilars is necessary not only to the US economy but to relieve the financial impact of serious illness on patients. Participating in biosimilar clinical trials can provide free access to these important medications. Physicians by participating in these trails can provide their patients with earlier access significantly reduce the financial burden on their patients.

Biography

Nigel Rulewski completed his medical degree, MB, BS at St Bartholomew’s Medical School, University of London. He also earned the Diploma of the Royal College of Obstetricians and Gynecologists and the Diploma of Child Health, Royal College of Physicians. He has held senior positions in the pharmaceutical industry over the last 25 years and is presently Vice President and Head of the Global Biosimilar Unit at Quintiles.

Nigel.Rulewski@quintiles.com